Company Analysis WuXi Biologics (Cayman) Inc.
1. Summary
Advantages
- The company's current efficiency (ROE=9.02%) is higher than the sector average (ROE=5.19%)
Disadvantages
- Price (13.38 HK$) is higher than fair price (11.28 HK$)
- Dividends (0%) are below the sector average (5.54%).
- The stock's return over the last year (-36.99%) is lower than the sector average (-28.09%).
- Current debt level 7.81% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| WuXi Biologics (Cayman) Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.6% | -4% | 2% |
| 90 days | 26.9% | -9.3% | 5.8% |
| 1 year | -37% | -28.1% | 20.9% |
2269 vs Sector: WuXi Biologics (Cayman) Inc. has significantly underperformed the "Healthcare" sector by -8.91% over the past year.
2269 vs Market: WuXi Biologics (Cayman) Inc. has significantly underperformed the market by -57.91% over the past year.
Stable price: 2269 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 2269 with weekly volatility of -0.7114% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (13.38 HK$) is higher than the fair price (11.28 HK$).
Price is higher than fair: The current price (13.38 HK$) is 15.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (30.83) is lower than that of the sector as a whole (35.42).
P/E vs Market: The company's P/E (30.83) is higher than that of the market as a whole (26.67).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.38) is lower than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (2.38) is higher than that of the market as a whole (-11.94).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.15) is lower than that of the sector as a whole (7.59).
P/S vs Market: The company's P/S indicator (6.15) is higher than that of the market as a whole (2.77).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (26.45) is higher than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (26.45) is higher than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 47.07% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (47.07%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-0.8813%).
5.4. ROE
ROE vs Sector: The company's ROE (9.02%) is higher than that of the sector as a whole (5.19%).
ROE vs Market: The company's ROE (9.02%) is higher than that of the market as a whole (6.3%).
5.5. ROA
ROA vs Sector: The company's ROA (6.41%) is higher than that of the sector as a whole (3.47%).
ROA vs Market: The company's ROA (6.41%) is higher than that of the market as a whole (3.39%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '5.54%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
